Standardized growth charts for children with osteogenesis imperfecta.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
15
09
2022
accepted:
17
02
2023
revised:
06
01
2023
medline:
24
8
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
Osteogenesis imperfecta (OI) is associated with short stature, which is mild, severe and moderate in OI types I, III and IV, respectively. Standardized OI type- and sex-specific growth charts across all pediatric ages do not exist. We assessed 573 individuals with OI (type I, III or IV), each with at least one height measurement between ages 3 months and 20 years (total 6523 observations). Analogous to the Centers for Disease Control pediatric growth charts, we generated OI type- and sex-specific growth charts for infants (ages 3-36 months) as well as children and adolescents (ages 2-20 years). Growth curves were fitted to the data using the LMS method and percentiles were smoothed. Age was associated with a decline in height z-scores (p < 0.001 for all OI types), which was more pronounced in females. Height multiplier curves were produced to predict adult height in children with OI. Among individuals with OI type I, those with COL1A1 pathogenic variants leading to haploinsufficiency were taller than those with COL1A1 or COL1A2 pathogenic variants not leading to haploinsufficiency. Our standardized OI type- and sex-specific growth charts can be used to assess the growth of individuals with OI from infancy to adulthood. Standardized osteogenesis imperfecta (OI) type- and sex-specific growth charts across all pediatric ages do not exist. Our study is the first to generate OI type- and sex-specific growth charts across all pediatric ages. Our height multiplier curves can be utilized to predict adult height in children with OI.
Sections du résumé
BACKGROUND
Osteogenesis imperfecta (OI) is associated with short stature, which is mild, severe and moderate in OI types I, III and IV, respectively. Standardized OI type- and sex-specific growth charts across all pediatric ages do not exist.
METHODS
We assessed 573 individuals with OI (type I, III or IV), each with at least one height measurement between ages 3 months and 20 years (total 6523 observations). Analogous to the Centers for Disease Control pediatric growth charts, we generated OI type- and sex-specific growth charts for infants (ages 3-36 months) as well as children and adolescents (ages 2-20 years). Growth curves were fitted to the data using the LMS method and percentiles were smoothed.
RESULTS
Age was associated with a decline in height z-scores (p < 0.001 for all OI types), which was more pronounced in females. Height multiplier curves were produced to predict adult height in children with OI. Among individuals with OI type I, those with COL1A1 pathogenic variants leading to haploinsufficiency were taller than those with COL1A1 or COL1A2 pathogenic variants not leading to haploinsufficiency.
CONCLUSION
Our standardized OI type- and sex-specific growth charts can be used to assess the growth of individuals with OI from infancy to adulthood.
IMPACT
Standardized osteogenesis imperfecta (OI) type- and sex-specific growth charts across all pediatric ages do not exist. Our study is the first to generate OI type- and sex-specific growth charts across all pediatric ages. Our height multiplier curves can be utilized to predict adult height in children with OI.
Identifiants
pubmed: 36922619
doi: 10.1038/s41390-023-02550-0
pii: 10.1038/s41390-023-02550-0
doi:
Substances chimiques
Collagen Type I, alpha2 Subunit
0
Collagen Type I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075-1082Informations de copyright
© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Forlino, A. & Marini, J. C. Osteogenesis imperfecta. Lancet 387, 1657–1671 (2016).
doi: 10.1016/S0140-6736(15)00728-X
pubmed: 26542481
Robinson, M.-E. & Rauch, F. Mendelian bone fragility bisorders. Bone 126, 11–17 (2019).
doi: 10.1016/j.bone.2019.04.021
pubmed: 31039433
Trejo, P. & Rauch, F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos. Int. 27, 3427–3437 (2016).
doi: 10.1007/s00198-016-3723-3
pubmed: 27492436
Jain, M. et al. Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genet Med. 21, 275–283 (2019).
doi: 10.1038/s41436-018-0045-1
pubmed: 29970925
Marr, C., Seasman, A. & Bishop, N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J. Multidiscip. Healthc. 10, 145–155 (2017).
doi: 10.2147/JMDH.S113483
pubmed: 28435282
pmcid: 5388361
Robinson, M. E., Rauch, D., Glorieux, F. H. & Rauch, F. Pubertal growth in osteogenesis imperfecta caused by pathogenic variants in Col1a1/Col1a2. Genet Med. 24, 1920–1926 (2022).
doi: 10.1016/j.gim.2022.05.008
pubmed: 35657380
Graff, K. & Syczewska, M. Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). Eur. J. Pediatr. 176, 311–316 (2017).
doi: 10.1007/s00431-016-2839-y
pubmed: 28058531
pmcid: 5321707
Barber, L. A. et al. Longitudinal growth curves for children with classical osteogenesis imperfecta (types III and IV) caused by structural pathogenic variants in type I collagen. Genet Med. 21, 1233–1239 (2019).
doi: 10.1038/s41436-018-0307-y
pubmed: 30270360
Paley, J. et al. The multiplier method for prediction of adult height. J. Pediatr. Orthop. 24, 732–737 (2004).
doi: 10.1097/01241398-200411000-00025
pubmed: 15502579
Paley, D., Matz, A. L., Kurland, D. B., Lamm, B. M. & Herzenberg, J. E. Multiplier method for prediction of adult height in patients with achondroplasia. J. Pediatr. Orthop. 25, 539–542 (2005).
doi: 10.1097/01.bpo.0000161095.15845.7d
pubmed: 15958911
Mortier, G. R. et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am. J. Med. Genet A 179, 2393–2419 (2019).
doi: 10.1002/ajmg.a.61366
pubmed: 31633310
Bardai, G., Moffatt, P., Glorieux, F. H. & Rauch, F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos. Int. 27, 3607–3613 (2016).
doi: 10.1007/s00198-016-3709-1
pubmed: 27509835
Montpetit, K., Palomo, T., Glorieux, F. H., Fassier, F. & Rauch, F. Multidisciplinary treatment of severe osteogenesis imperfecta: functional outcomes at skeletal maturity. Arch. Phys. Med. Rehabil. 96, 1834–1839 (2015).
doi: 10.1016/j.apmr.2015.06.006
pubmed: 26140741
Robinson, M. E., Trejo, P., Palomo, T., Glorieux, F. H. & Rauch, F. Osteogenesis imperfecta: skeletal outcomes after bisphosphonate discontinuation at final height. J. Bone Miner. Res. 34, 2198–2204 (2019).
doi: 10.1002/jbmr.3833
pubmed: 31356699
Fassier, F. Fassier-Duval telescopic system: how I do it? J. Pediatr. Orthop. 37, S48–S51 (2017).
doi: 10.1097/BPO.0000000000001024
pubmed: 28799995
Ogden, C. L. et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics Version. Pediatrics 109, 45–60 (2002).
doi: 10.1542/peds.109.1.45
pubmed: 11773541
Cole, T. J. Fitting smoothed centile curves to reference data. J. R. Stat. Soc. Ser. A (Stat. Soc.) 151, 385–418 (1988).
doi: 10.2307/2982992
Butler, M. G. et al. Growth charts for non-growth hormone treated Prader-Willi syndrome. Pediatrics 135, e126–e135 (2015).
doi: 10.1542/peds.2014-1711
pubmed: 25489013
pmcid: 4279067
Cole, T. J. & Green, P. J. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat. Med. 11, 1305–1319 (1992).
doi: 10.1002/sim.4780111005
pubmed: 1518992
Germain-Lee, E. L. et al. Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for clinical care. Pediatr. Res. 79, 489–495 (2016).
doi: 10.1038/pr.2015.230
pubmed: 26539664
Zemel, B. S. et al. Growth charts for children with Down syndrome in the United States. Pediatrics 136, e1204–e1211 (2015).
doi: 10.1542/peds.2015-1652
pubmed: 26504127
Horton, W. A., Rotter, J. I., Rimoin, D. L., Scott, C. I. & Hall, J. G. Standard growth curves for achondroplasia. J. Pediatr. 93, 435–438 (1978).
doi: 10.1016/S0022-3476(78)81152-4
pubmed: 690757
Patel, P. et al. Growth charts for patients with Hunter syndrome. Mol. Genet Metab. Rep. 1, 5–18 (2014).
doi: 10.1016/j.ymgmr.2013.10.001
pubmed: 24955330
pmcid: 4060980
Muschol, N. M. et al. Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III). Orphanet J. Rare Dis. 14, 93 (2019).
doi: 10.1186/s13023-019-1065-x
pubmed: 31046785
pmcid: 6498678
Montano, A. M., Tomatsu, S., Brusius, A., Smith, M. & Orii, T. Growth charts for patients affected with Morquio A disease. Am. J. Med. Genet A 146A, 1286–1295 (2008).
doi: 10.1002/ajmg.a.32281
pubmed: 18412124
Quartel, A. et al. Growth charts for individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). JIMD Rep. 18, 1–11 (2015).
pubmed: 25518809
Ben Amor, I. M., Roughley, P., Glorieux, F. H. & Rauch, F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in Col1a1. J. Bone Min. Res. 28, 2001–2007 (2013).
doi: 10.1002/jbmr.1942
Ma, J. et al. Impact of vertebral fractures and glucocorticoid exposure on height deficits in children during treatment of leukemia. J. Clin. Endocrinol. Metab. 104, 213–222 (2019).
doi: 10.1210/jc.2018-01083
pubmed: 30247635
Rauch, F., Lalic, L., Roughley, P. & Glorieux, F. H. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J. Bone Min. Res. 25, 1367–1374 (2010).
Rauch, D. et al. Assessment of longitudinal bone growth in osteogenesis imperfecta using metacarpophalangeal pattern profiles. Bone 140, 115547 (2020).
doi: 10.1016/j.bone.2020.115547
pubmed: 32730936
pmcid: 7502481
Zeitlin, L., Rauch, F., Plotkin, H. & Glorieux, F. H. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111, 1030–1036 (2003).
doi: 10.1542/peds.111.5.1030
pubmed: 12728084
Sanguinetti, C., Greco, F., De Palma, L., Specchia, N. & Falciglia, F. Morphological changes in growth-plate cartilage in osteogenesis imperfecta. J. Bone Joint Surg. Br. 72, 475–479 (1990).
doi: 10.1302/0301-620X.72B3.2187879
pubmed: 2187879
Grafe, I. et al. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 20, 670–675 (2014).
doi: 10.1038/nm.3544
pubmed: 24793237
pmcid: 4048326
Tauer, J. T., Abdullah, S. & Rauch, F. Effect of anti-TGF-beta treatment in a mouse model of severe osteogenesis imperfecta. J. Bone Min. Res. 34, 207–214 (2019).
doi: 10.1002/jbmr.3617
Wang, W., Rigueur, D. & Lyons, K. M. TGFβ signaling in cartilage development and maintenance. Birth Defects Res. C. Embryo Today 102, 37–51 (2014).
doi: 10.1002/bdrc.21058
pubmed: 24677722
pmcid: 4267887
Nicol, L. E. et al. Alterations of a serum marker of collagen X in growing children with osteogenesis imperfecta. Bone 149, 115990 (2021).
doi: 10.1016/j.bone.2021.115990
pubmed: 33932621
pmcid: 8217291
Palomo, T., Glorieux, F. H., Schoenau, E. & Rauch, F. Body composition in children and adolescents with osteogenesis imperfecta. J. Pediatr. 169, 232–237 (2016).
doi: 10.1016/j.jpeds.2015.10.058
pubmed: 26593106
Tauer, J. T., Robinson, M. E. & Rauch, F. Osteogenesis imperfecta: new perspectives from clinical and translational research. JBMR 3, e10174 (2019).